Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDR | P35968 | 17/20 | 0.68 |
| ▸ | CNR1 | P21554 | 1/20 | 0.51 |
| ▸ | LIMK1 | P53667 | 1/20 | 0.49 |
| ▸ | ABL1 | P00519 | 1/20 | 0.49 |
| ▸ | LCK | P06239 | 1/20 | 0.49 |
| ▸ | CSF1R | P07333 | 1/20 | 0.49 |
| ▸ | PDGFRB | P09619 | 1/20 | 0.49 |
| ▸ | MAP2K2 | P36507 | 1/20 | 0.49 |
| ▸ | CDK7 | P50613 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6328597 | 0.87 | KDR (0.64) | KDR | |
| SCHEMBL7228893 | 0.82 | KDR (0.63) | KDRCNR1 | |
| SCHEMBL7237283 | 0.81 | KDR (1.00) | KDRCNR1ABL1LCKCSF1R | |
| SCHEMBL3651635 | 0.81 | KDR (1.00) | KDR | |
| SCHEMBL6332623 | 0.81 | KDR (0.79) | KDRCNR1LIMK1 | |
| SCHEMBL6330201 | 0.80 | KDR (0.68) | KDRCNR1LIMK1 | |
| SCHEMBL6330223 | 0.80 | KDR (0.71) | KDRCNR1 | |
| SCHEMBL6336657 | 0.79 | KDR (0.63) | KDRCNR1 | |
| SCHEMBL6336582 | 0.79 | KDR (0.63) | KDRCNR1 | |
| SCHEMBL6335500 | 0.78 | KDR (0.74) | KDRCNR1LIMK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20050228031-A1 | Tyrosine kinase inhibitors | BILODEAU MARK T | 2005-10-13 | — | — | US | claimed |
| US-20050228031-A1 | Tyrosine kinase inhibitors | BILODEAU MARK T | 2005-10-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050228031-A1 | Tyrosine kinase inhibitors | ERBB2, TYRO3, TIE1 | KDR 5/4885CNR1 3794/4885LIMK1 189/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.